DIRS.INFO The most relevant business & tech news

☆ Here are Thursday's biggest analyst calls: Nvidia, Tesla, Ford, Super Micro, Wendy's, Hasbro, Take-Two, Wynn & more
▼ + stars: | 2024-05-23 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Bank of America reiterates Nvidia as buy Bank of America raised its price target on the stock to $1,320 per share from $1,100 following earnings. Deutsche Bank initiates Freshpet a buy Deutsche said it sees "multiple structural tailwinds" for shares of the pet food and health company. Deutsche Bank initiates BellRing Brands as buy Deutsche said it sees a long runway for growth for the food company. " Deutsche Bank initiates Legend Biotech as buy Deutsche said it's bullish on the biotech company's multiple myeloma drug Carvykti. Bank of America reiterates Super Micro Computer as buy Bank of America said Nvidia's earnings report on Wednesday bode well for companies like Super Micro.

Persons: Bernstein, Ford, Morgan Stanley downgrades NetEase, Morgan Stanley, Evercore, BRBR, Wedbush, Jefferies, GDRX, Oppenheimer, Armour, Kevin, Dell, Chubb, Stephens, FHN, Tesla, Argus, it's bullish, bode Organizations: " Bank of America, Nvidia, Bank of America, Deutsche Bank, Deutsche, BellRing Brands, JPMorgan, Hasbro, RBC, Norfolk Southern, NSC, GE Vernova, GE, UBS, Eastman Chemical, Eastman, SAP, underperform Bank of America, Berkshire Hathaway's, of America, Rockstar Games, NextEra Energy Partners, Argus, Wynn, Biotech, Computer Locations: U.S, China, Berkshire, Macau, Las Vegas, 2H24

But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.

Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City

☆ Stocks making the biggest moves midday: Tesla, GE HealthCare, Coinbase and more
▼ + stars: | 2024-03-13 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Crypto stocks — Stocks whose performance is tied to the price of bitcoin rose as the cryptocurrency pushed to another record for the third day in a row. Dollar Tree posted adjusted earnings of $2.55 per share on $8.64 billion of revenue for the fourth quarter. Analysts surveyed by LSEG, formerly known as Refinitiv, had penciled in $2.65 per share on $8.67 billion in revenue. GE HealthCare — Shares dropped 3% after the medtech company announced a secondary offering of 13 million shares. Analysts had expected earnings of 2 cents per share on revenue of $1.62 billion, per LSEG.

Persons: Coinbase, MicroStrategy, CleanSpark, Baird, Goldman Sachs, Wells, Raymond James, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Marathon, Iris Energy, Texas, Nvidia, Devices, Micron Technology —, Micron, AMD, LSEG, GE, —, GE HealthCare Technologies, General Electric, Royal, Petco, Wellness Locations: Kentucky, Royal Caribbean

☆ Johnson & Johnson forecasts as much as 6% sales growth in 2024
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

Dec 5 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. Sales of blockbuster psoriasis treatment Stelara in Europe are expected to come under pressure as early as next year as a key patent on the drug expires. Sales of the drug largely come from its use as a treatment for inflammatory bowel diseases (IBD), Wolk said. J&J's 2024 revenue growth forecast excludes sales of its COVID vaccine.

Persons: Johnson, Joseph Wolk, Wolk, J, Bhanvi, Patrick Wingrove, Anil D'Silva Organizations: Johnson, Thomson Locations: Europe, United States, Bengaluru, New York

☆ US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
▼ + stars: | 2023-11-20 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The U.S. Food and Drug Administration (FDA) has not yet confirmed when the advisory panel would meet, they added. Shares of Bristol Myers Squibb fell more than 2% and those of 2seventy bio slid nearly 20% in early morning trade. The therapy was originally co-developed by bluebird bio (BLUE.O) but following its spin-off in 2021 became part of 2seventy's portfolio. Bristol Myers and 2seventy bio, however, have faced manufacturing constraints, and a month-long planned maintenance shutdown of one of Abecma's manufacturing facility in June had also negatively impacted sales.

Persons: Andrew Kelly, 2seventy bio's, Bristol Myers, Johnson, Biotech's, Khushi, Sriraj Kalluvila Organizations: Food and Drug Administration, FDA, REUTERS, Bristol Myers Squibb, U.S . Food, Drug Administration, Bristol, Johnson, Thomson Locations: White Oak , Maryland, U.S, Bengaluru

☆ Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside
▼ + stars: | 2023-11-06 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Legend Biotech has a best-in-class product and could become a global leader in the cell and gene therapy space, according to Goldman Sachs. "We believe Legend has the potential to grow into a leading global cell therapy company," Chen said in a note to clients. Its leading therapy in the space is Carvykti, which he described as "best-in-class." In partnership with Johnson & Johnson , Carvykti is undergoing capacity expansion in the U.S. and European Union to meet demand. Legend stock rose 0.3% in Monday's session.

Persons: Goldman Sachs, Ziyi Chen, Chen, Johnson, Carvykti, — CNBC's Michael Bloom Organizations: Biotech, Johnson, Union Locations: U.S

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Amazon, BJ's, Ferrari, Disney, Birkenstock & more
▼ + stars: | 2023-11-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Monday's biggest calls on Wall Street: KBW upgrades Bank of America to market perform from underperform KBW upgraded the banking giant with long-term rates declining. Bank of America downgrades Paramount to underperform from buy Bank of America said the backdrop is too challenging for the media stock. Bank of America reiterates Nvidia as buy Bank of America said it's bullish on the stock heading into earnings later this month. Goldman Sachs initiates Birkenstock as buy Goldman initiated the shoe company with a buy and said Birkenstock shares are compelling. Bank of America reiterates Apple as neutral Bank of America said it's sticking with its neutral rating on shares of Apple .

Persons: KBW, Mizuho, it's, BILI, Lee jeans, it's bullish, Goldman Sachs, Goldman, EBITDA, Raymond James downgrades Bloomin, Raymond James Organizations: Bank of America, Underperform, Corp, Deutsche Bank, Deutsche, Mizuho, TAM, UBS, Amazon, Citi, Disney, " Bank of America, Paramount, Barclays, Nvidia, AMD, Dominion, Biotech, JPMorgan, HSBC, RBC, Apple, of America Locations: China, FY24E, CLX, Russia, Ukraine

☆ 2seventy bio to lay off 40% of workforce; CEO to step down
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +2 min

Nick Leschly, CEO of bluebird, speaks at the opening of Lonza Houston, the world’s largest dedicated cell and gene therapy facility, in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer Acquire Licensing RightsSept 12 (Reuters) - 2seventy bio (TSVT.O) said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in premarket trade. The company added that CEO Nick Leschly will step down and transition to the role of chairman. Leschly was earlier the CEO of bluebird bio (BLUE.O) for 11 years, but changed role after the gene therapy maker's oncology portfolio was spun off from it as 2seventy. The company will now focus on another type of multiple myeloma patients, for which it expects approval from the U.S. Food and Drug Administration in mid-December.

Persons: Nick Leschly, Lonza, Daniel Kramer, Leschly, 2seventy, Abecma, Johnson, Bristol Myers, William Baird, Pratik Jain, Shounak Dasgupta, Maju Samuel Organizations: bluebird, REUTERS, Johnson, Legend Biotech, Bristol, Bristol Myers Squibb, U.S . Food, Drug Administration, Thomson Locations: Lonza Houston, Houston , Texas, U.S, Abecma, Bengaluru

☆ J&J's strong quarter was amplified by new details around its big Kenvue consumer unit stake
▼ + stars: | 2023-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Johnson & Johnson (JNJ) reported strong second - quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. It's possible that J & J management will offer up Kenvue shares at a discount to market value. Regardless, arbitrage isn't our game and we want to be invested in J & J for the long term. The only change — since J & J owns 89.6% of Kenvue — is that 10.4% of earnings generated since Kevnue went public in early May to the end of the quarter are no longer attributed to J & J. A Johnson & Johnson building is shown in Irvine, California.

Persons: Johnson, —, Kevnue, J, J's, prioritization, Jim Cramer's, Jim Cramer, Jim, Mike Blake Organizations: Dow, Pharmaceutical, Management, J's, Johnson, J, Consumer, Consumer Health, Pharmaceutical Pharmaceutical, CNBC, & $ Locations: Kenvue, JNJ, KVUE, Spravato, Irvine , California

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

☆ Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
▼ + stars: | 2023-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Still, the outlook for biotech stocks could improve now , with innovation in new drugs and more merger and acquisition activity driving investor interest. Recently, Wall Street has been zoning in on developments in treatments for Alzheimer's diseases, drugs for weight loss and treatments using gene editing. CNBC Pro screened for biotech stocks that are part of the iShares Biotechnology ETF , searching for names with huge upside from current prices. In January, Piper Sandler initiated research coverage of Karuna with an overweight rating, saying it's "blazing a new trail in Schizophrenia" treatments. The stock was named another top 2023 pick by Piper Sandler, which said Legend has a "best-in-class" treatment for adults with relapsed multiple myeloma, a segment "with demand far outpacing supply."

☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
▼ + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.

☆ What to watch for as J&J gets ready to split into two separate companies next year
▼ + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +11 min

During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.

Organizations: & $

Search resuls for: "Carvykti"

13 mentions found